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Ovine enzootic abortion (OEA), caused by Chlamydia abortus, is an economically
important disease inmany countries. Inactivated vaccines have been used for many years
as they induce immunity in sheep, although outbreaks of abortions have been described
in vaccinated flocks. In addition, there is a commercially available live attenuated vaccine
that provides good protective results. Recently however, reports question the attenuation
of this vaccine and associate it with the appearance of outbreaks of OEA in vaccinated
flocks. In the present study, a recently commercialized inactivated vaccine (INMEVA®;
Laboratorios Hipra S.A., Amer, Spain) has been evaluated using mouse and sheep
experimental models. In the mouse models (non-pregnant and pregnant models), the
efficacy of INMEVA vaccine has been compared to an unvaccinated control group and
to an experimental inactivated vaccine considered as a positive protection control (UMU
vaccine). In the non- pregnant model, the UMU vaccine was more effective than the
INMEVA vaccine regarding the impact on body weight or the presence ofC. abortus in the
liver, but both vaccinated groups (UMU and INMEVA) had significantly lower C. abortus
in the liver compared to the control group. In the pregnant model in terms of reproductive
failures, pups per mouse or the presence of C. abortus in the liver or uterus, no significant
differences were found between both vaccines, inducing protection compared to the
control group. In the ovine pregnant model, where INMEVA vaccine was compared
only to an unvaccinated group, the results indicate that this new commercial vaccine
is safe and provides a suitable level of protection against an experimental challenge with
C. abortus. A 75% reduction in reproductive disorders, 55% reduction in animals with
C. abortus shedding on day of parturition/abortion, and a significant reduction of the
average amount of chlamydial shedding from parturition/abortion over the next 21 days
was observed, in relation to the infected control group. The results suggest that this
vaccine is adequate for the control and prevention of OEA; however, future studies are
necessary to elucidate the type of protective immune response that it induces.
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INTRODUCTION
Ovine enzootic abortion (OEA), caused by Chlamydia abortus,
an obligate intracellular Gram-negative bacterium belonging to
the Chlamydiaceae family, is an economically important disease
in many countries. In fact, OEA is one of the major causes of
small ruminant abortion and is found throughout the world
(including North America, Europe and Africa), but not in
Oceania (Australia and New Zealand) (1). In addition, it has been
described that C. abortus can cause miscarriages in women (2)
and atypical pneumonia in humans (3) as a zoonotic agent. The
infection results in a purulent placentitis, leading to reproductive
failures such as late-term abortion, premature lambing with
neonatal death or the birth of weak lambs (4). The disease spreads
easily in infected flocks, particularly at lambing time when
ewes shed large amounts of C. abortus via vaginal discharges
at abortion or parturition (placenta and fetuses). On the other
hand, this infection will provide an effective immune response
in OEA-affected ewes, protecting from future C. abortus-induced
abortions. They could, however, shed the bacteria in subsequent
estrus or parturition, maintaining the risk of infection in the flock
(5). The ingestion of contaminated material or inhaling aerosols
can infect susceptible animals (6). After an infection of a naïve
ewe it is believed that C. abortus may remains in a latent state in
lymphoid tissue, controlled by cytokines like IFN-γ (7), and may
not show clinical signs until the last weeks of the next gestation,
leading to potential reproductive failure. The reproductive failure
rate in an endemically infected flock is around 10%, whereas in a
newly infected naïve flock it is around 30%, up to 60% in goat
herds (4).
In the last 60 years, different inactivated vaccines prepared
from egg grown or cell cultures have been commercialized for
preventing OEA. Nevertheless, the efficacy of these vaccines
has been questioned, as in some cases, outbreaks have been
described in vaccinated flocks (8–10). Inactivated vaccines can
reduce the incidence of abortions and the shedding of C. abortus
at parturition, but they do not prevent shedding completely.
This fact can cause endemic cycles of infection, with serious
consequences for the OEA epidemiology (11). The outcome of
this lack of efficacy is that most of these vaccines have been
removed from the market (10). To overcome this problem, live
temperature-sensitive attenuated vaccines have been developed,
represented by the 1B strain derived from the wild-type AB7
strain after nitrosoguanidine (NTG) treatment (12). This vaccine
is commercially available and good results in protecting against
C. abortus-induced abortion in field trials have been reported
(6, 13). However, given the zoonotic capacity of the pathogen, as
well as the recently reported occurrence of abortive outbreaks in
vaccinated flocks, in which the vaccine strain was involved, this
attenuated vaccine raises safety risks. Indeed, after identification
by PCR-RFLP of several single nucleotide polymorphisms (SNPs)
exclusive to the vaccine strain 1B (14), it was possible to
discriminate between wild-type field strains from the vaccine
strain, and the vaccine strain was identified in abortions of
vaccinated animals (15–19), where some unvaccinated animals
suffered abortions caused by this vaccine strain. In addition, in a
recent study, Longbottom et al. (19) question the true attenuation
of the vaccine strain and have concluded that the protection of
the 1B vaccine is unlikely to be due to the NTG induced SNPs
and is more likely caused by the administration of high doses of
C. abortus elementary bodies that stimulate protective immunity,
similar to a natural infection.
Other vaccine approaches, such as subcellular vaccines or
DNA vaccines, have recently been studied. The major outer
membrane protein (MOMP) has been the main focus of
subcellular vaccines, where protection has been described by
using its native oligomer form (20). Vaccines comprising the
chlamydial outer membrane complex provided good protection
against OEA (21). However, the large quantities of Chlamydiae
needed for vaccine preparation have made it economically
unfeasible for an ovine vaccine (22). Studies conducted to
assess the efficacy of recombinant MOMP against C. abortus
experimental infection have been discouraging (23). In a recent
study, O’Neill et al. (24) demonstrated 50% efficacy when two
recombinant proteins were administered together in a pregnant
ovine model. Nonetheless, bacterial shedding was not reduced.
Finally, all attempts to get a DNA vaccine against OEA have
failed to induce a protective immune response [reviewed in (25)].
Despite the different approaches in the design of vaccines against
C. abortus, there is still a lack of safe and efficacious vaccines in
terms of shedding and reproductive disorders.
The mouse models have proven to be a well-controlled
experimental animal model for assessing the efficacy of
experimental or commercial vaccines (26–29). In fact, it has been
shown that intraperitoneal inoculation of C. abortus between
7 and 11 days of gestation in mice induces colonization of
the placenta, leading to abortion and the shedding of C.
abortus (30). Similarly to the experimentally-induced or natural
disease in ewes. In addition, this model has been used to test
different adjuvant and vaccine-production procedures for the
development of new inactivated vaccines against OEA (28). In
that previous study, the efficacy of a new experimental inactivated
vaccine was demonstrated. In this context, the first aim of this
study was to test a new inactivated vaccine against OEA that has
recently been commercialized in different European countries
under the name INMEVA R© (Laboratorios HIPRA, S.A., Amer,
Spain). To do that, a pregnant mouse model challenged with
C. abortus at mid gestation was used to assess INMEVA and
compare it to the efficacious experimental inactivated vaccine.
However, as it was necessary to test this vaccine on the target
animals, the second aim was to evaluate the efficacy of the new
commercial inactivated vaccine in a pregnant sheep model.
MATERIALS AND METHODS
Mice and Housing
Seven- to eight-week-old female Swiss OF1 mice were purchased
from Harlan UK Limited (Bicester, UK). All of them were free
of common bacterial and viral pathogens based on the results
of routine screening procedures conducted by the suppliers. The
food and water were offered ad libitum and mice were kept in
cages in an environmentally controlled room. The study was
conducted at the animal facilities of the University of Murcia
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(UMU, Murcia, Spain). All handling practices were endorsed
by the local government and followed the recommendations of
Directive 2010/63/EU of the European Parliament and of the
Council on the protection of animals used for scientific purposes
and the Bioethical Committee of the University of Murcia, Spain
(approval number A13150202; date of approval 24 February
2015). All animals enrolled in the study were handled following
strictly the good clinical practices and all efforts were taken to
minimize suffering.
Ewes and Housing
Eighty primiparous ewes of the breed “Churra” were purchased
from a flock in Castilla y León (north-western Spain) with
no known previous cases of Chlamydia abortus and which
had not been administered any previous vaccine against OEA.
These ewes were serologically screened for C. abortus (using ID
Screen R© Chlamydophila abortus Indirect Multi-species, ID.VET,
France), Salmonella Abortusovis (using an in-house ELISA test,
Hipra, Spain), Brucella spp. (using ID Screen R© Brucellosis Serum
Indirect Multi-species, ID-VET, France), Toxoplasma gondii
(using ID Screen R© Toxoplasmosis Indirect Multi-species, ID-
VET, France), Coxiella burnetii (using ID Screen R© Q Fever
Indirect Multi-species, ID-VET, France), and Maedi-Visna virus
(using ID Screen R© MVV/CAEV Indirect, ID-VET, France)
before being included in the study. The group size used was
determined to contain at least 15 pregnant ewes. This group
size (n = 15) was based upon a 75% reduction in reproductive
disorders caused by C. abortus (such as abortions in late
pregnancy, premature lambing or the birth of weak lambs)
after challenge in vaccinated vs. control animals. The estimated
percentage of reproductive disorders of ewes becoming infected
with C. abortus in the control group was 65%. Consequently,
a 16.25% of reproductive disorders was estimated in the
vaccinated group. The required number of animals (n = 15)
was obtained using the Ene 3.0 software (Servei d’Estadística
Aplicada, Universitat Autonoma de Barcelona and the Biometric
Department of GlaxoSmithKline, Bellaterra, Spain), considering
a power (1-β) of 0.80 and α of 0.05. Sixty ewes were then
randomly divided into two experimental groups of 30 animals
(vaccinated and control group). An additional group of 20
animals was included as a sentinel group (not infected). Ewes
were randomly divided into three experimental groups (A, B,
or C). Distribution of these ewes into 3 groups was performed
by sorting those ewes based on their body weight 2 days prior
to vaccination. Five cohorts of 16 ewes were generated; Cohort
1 contained the 16 ewes with the lowest body weight, whereas
cohort 5 contained the 16 ewes with the highest body weight. A
random number was generated using computer software (Excel
2013, Microsoft Corp., Redmond, WA). The six ewes with the
lowest random numbers of each cohort were assigned to group
A. The six ewes with the highest random numbers of each
cohort were assigned to Group B. The remaining 4 ewes per
cohort, with the intermediate random number were assigned to
Group C. Consequently, 30 ewes were assigned to the vaccinated
group (39.0 ± 0.89 kg), another 30 ewes were assigned to the
control group (39.19± 0.91 kg) and 20 ewes were assigned to the
sentinel group (39.4 ± 0.93 kg). Ewes were uniquely identified
with paired, sequentially numbered ear tags, 1 in each ear. The
study was conducted in the Instituto de Ganadería de Montaña
(CSIC-Universidad de León, León, Spain). All sheep were handle
following the recommendations of Directive 2010/63/EU of the
European Parliament and of the Council on the protection
of animals used for scientific purposes and the CSIC Animal
Experimentation Committee (ref. OH/406-2016). This phase was
conducted over a 9-month period from August to April on an
experimental farm (Grulleros, Spain), where the average low
and high ambient temperatures were 4 and 18◦C, respectively.
Relative humidity ranged from 44% (average daily low) to 89%
(average daily high). During the vaccination phase, all ewes were
housed together in a single pen with straw bedding and physically
separated from other animals. Bedding material was replaced
weekly. Food and water were offered ad libitum during the study.
Five and 2 weeks before mating, all animals received
2mL of vaccine or PBS subcutaneously. Then, ewes
were estrus-synchronized through vaginal sponges with
medroxyprogesterone acetate (Esponjavet, HIPRA, Spain) for 14
days and subsequent intramuscular inoculation of mare serum
gonadotropin (Oviser, HIPRA, Spain). All animals were then
mated with pure-breed Churra rams during 2 days, after that
the ewes were separated from the rams; all those rams were
serologically negative to C. abortus. Gestation and fetal viability
were diagnosed by ultrasound scanning (US) on day 45 post-
mating. Non-pregnant animals were withdrawn from the study.
A total of 50 ewes were pregnant: 19 vaccinated, 21 control,
and 10 sentinels. All these pregnant ewes were enrolled in the
challenge phase. During this phase, infected ewes were housed
together in four pens of 10 animals each, to minimize the stress
of handling during the sampling and to facilitate the detection of
abortions. The sentinel group was housed in a separate pen. All
these pens had straw bedding and were physically separated from
other animals. New straw bedding was added approximately
weekly. Food and water were offered ad libitum during the study.
Vaccines and Inoculum
The vaccine evaluated in the present study was an inactivated
vaccine of Salmonella enterica subsp. enterica serovar
Abortusovis and Chlamydia abortus (INMEVA R©; Laboratorios
Hipra S.A., Amer, Spain). This vaccine contains the A22
strain of C. abortus inactivated by a method involving nucleic
acids but not surface proteins. This vaccine has a mixture of
aluminum hydroxide and diethylaminoethyl (DEAE) dextran as
an adjuvant.
The abortion-causing C. abortus AB7 strain (31) was used to
prepare the homologous vaccine (experimental vaccine UMU)
in the experiment 1 developed in the murine model. This strain
was also used to prepare the inoculums of murine models
and ovine model. The bacterial strain was inoculated into yolk
sacs of developing chicken embryos. Inoculum titration was
performed by enumerating the inclusion-forming units (IFU)
in McCoy cells, and then the standardized aliquots were frozen
at −80◦C until use. To perform the infection, freshly thawed
vials were diluted with sterile phosphate-buffered saline (PBS)
0.1M pH 7.2 to final concentrations of 2 × 105 IFUs/mL for
non-pregnant mice, 5 × 104 IFUs/mL for pregnant mice or 1.5
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× 106 IFUs/mL for ewe challenge. Challenged mice received
0, 2mL intraperitoneally and pregnant ewes were challenged
subcutaneously with 2mL. The homologous vaccine (UMU)
using the AB7 strain was developed as previously described by
Caro et al. (28). This experimental vaccine was inactivated by
binary ethylenimide (BEI) and adjuvated with the semi-purified
derivate of saponin QS-21. This UMU experimental vaccine
has been previously tested showing that it induces excellent
protective results in differentmousemodels [reviewed in (29)], so
it was used as a positive protection control in the murine models.
Study Design of Experiment 1 (Mice)
All mice were enrolled in the study 7 days before vaccination.
Mice were randomly distributed in four groups. Group A (n
= 20) was immunized subcutaneously with the new inactivated
vaccine of C. abortus (INMEVA). Group B (n = 20) was
immunized with the homologous inactivated vaccine of C.
abortus (UMU). Group C (n = 20) was mock-vaccinated with
PBS as a control group. Group D (n = 10) was monitored
as a sentinel group. Animals of groups A, B, and C received
0.2mL of vaccine or PBS subcutaneously in the back on the right
of the midline on day 0 and 14 days later on the left of the
midline. (Figure 1A). General appearance and possible clinical
signs were monitored daily. Once a week the injection sites were
palpated to detect signs of pain and examine for swelling. Three
weeks post-boost (day 35 of study), mice were mated, and the
detection of a vaginal plug was considered as day 0 of gestation.
All pregnant mice and six non-pregnant mice from groups A, five
non- pregnant mice of group B and five non- pregnant mice of
group C were infected 33 days after administering the post-boost
(day 47 of study). Consequently, in pregnant animals, challenge
was conducted at 12 days of gestation (Figure 1A). All mice were
monitored to assess demeanor throughout the entire study.
After challenge, non-pregnant mice were monitored daily to
evaluate mortality, and body weight was recorded on the day of
challenge (D47) and the day of necropsy (D51). Pregnant mice
were monitored daily for mortality, abortions and the number of
live offspring per litter from the experimental infection to the day
of necropsy (11 days after challenge). On the day of necropsy all
animals were euthanized and sampled to detect the presence of
C. abortus from liver and from the uterine horn in the case of the
pregnant animals.
Study Design of Experiment 2 (Ewes)
All ewes were enrolled in the study 14 days before the vaccination.
The ewes of group A (n = 30) were immunized with the new
inactivated vaccine INMEVA, whereas the other two groups,
control and sentinel (B and C; n = 30 and 20, respectively), were
administered PBS (Figure 1B).
During the vaccination phase, from vaccination until
diagnosis of gestation, general clinical signs were monitored
daily. Subsequently, all 40 pregnant ewes of groups A (n = 19)
and B (n = 21) were challenged subcutaneously on day 75 of
gestation. Group C (n = 10) was not infected, remaining as a
sentinel group.
During the challenge phase, visual examinations were
conducted to assess ewe demeanor and reproductive incidences
(abortions in late pregnancy, premature lambing or the birth
of weak lambs, etc.), which were recorded daily from challenge
until 1 month after parturition/abortion. In the event of an
abortion, vaginal swabs, lung samples from the fetus, or dead
lamb, and placenta samples were collected. Furthermore, to
assess the shedding of C. abortus, vaginal swabs were collected
from all infected ewes on the day of challenge, the day of
abortion or parturition and then three times a week during
the 21 days following the day of abortion or parturition. All
those samples collected from aborted fetuses or dead lambs,
and vaginal swabs were analyzed by qPCR, as described in
the following section. Rectal temperatures of all animals were
recorded daily from 3 days before challenge to 5 days after
challenge. Body weight of lambs was recorded at parturition and
then 4, 7, 11, 14, 18, 21, 25, and 28 days post-partum. If an
abortion occurred, macroscopic evaluation of the placenta and
fetuses was carried out. Next, samples from placenta and fetal
brain, lung, and liver were fixed in 10% buffered formalin and
further processed for conventional histopathological evaluation
and labeling of chlamydia. Immunohistochemical detection of
the chlamydial antigen was carried out following the same
previously published technique (32). The personnel involved
in the animal experimental procedures, who gathered data on
different parameters, were not aware of the treatment received
by each individual ewe because ewes and treatments were
randomized by a treatment dispenser who was not involved in
gathering data.
Isolation of C. abortus
In mice experimental design, the evaluation of the infection was
performed by counting the IFUs of the liver and spleen isolated
on McCoy cell monolayers, based on the method previously
described by Buendia et al. (33). The number of inclusions
in McCoy cells was counted under fluorescent microscopy to
calculate the number of IFUs per gram of tissue. The analysis of
the persistence of C. abortus in the uterus was conducted taking
a complete uterine horn, which had at least four sites of previous
placental attachment, and following the procedure used for the
other tissues, to calculate the number of IFUs per uterine horn.
This method has a detection limit of 66.6 IFUs per horn.
C. abortus Quantitative PCR
Referring to the ovine experiment, vaginal swabs were
resuspended in 1.5mL of sterile PBS and tissue samples diluted
1/5 w/v with sterile PBS and homogenized. The DNEasy Blood
and Tissue Kit (Qiagen, Las Rozas, Madrid) was used to process
the samples, following the instructions of the manufacturer. All
samples of DNA extracted was analyzed using a TaqMan PCR for
quantification of C. abortus. The omp A gene of C. abortus was
amplified following the method described by Pantchev et al. (34).
Real-time PCR was performed in duplicate using the QuantiFast
Pathogen IC PCR kit (Qiagen) as universal PCR Master Mix in a
final volume of 25 µL per reaction. The mixture included 5 µl
of sample DNA, 1 µL of internal control assay, 1 µL of internal
control DNA, each primer (Cpa OMP1-F and Cpa OMP1-R) at
the final concentration of 0.9 and 0.2µM of Cpa OMP1 probe.
Amplification was carried out on a Light Cycler 480 (Roche)
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FIGURE 1 | Experimental designs for the mouse model (A) and the ovine model (B). The diagrams illustrate the days (D) of the different interventions on the animals
used in both experiments. The day of gestation is indicated for pregnant animals (G).
thermocycler, using the following cycling parameters: 95◦C for
5min (single denaturation step), 45 cycles of 95◦C for 15 s and
60◦C for 1min (annealing and extension). The fluorescence data
was collected using the ROX and FAM filters during the 60◦C
annealing step.
A 10-fold serial dilution of inoculum of C. abortus (108
IFU/mL) were made and the extraction of DNA was done in each
diluted sample using the same protocol as the samples to create
a standard curve to estimate the number of genome copies of C.
abortus in each sample.
Calculation and Statistical Analysis
Body weights per group of the non- pregnant mice on day 47
(challenge day) and day 51 were compared per day using PROC
MIXED in SAS (SAS Institute Inc., Cary, NC), treating a day
as a repeated measure. The model included the fixed effects of
day, treatment, day-by-treatment interaction, and the random
effect of animal within the treatment. Compound symmetry
was selected as the variance-covariance matrix structure on the
basis of best fit according to Schwarz’s Bayesian information
criterion. Using these data, the percentage of body weight gain
per animal was calculated as the difference between final body
weight (D51) minus the body weight on challenge day (D47)
divided by the body weight of challenge day. These percentages
from the different groups were compared using ANOVA in SAS.
The data of amount of C. abortus (IFUs/mL) isolated in the liver
samples were log-transformed to fulfill normality assumptions.
The amount of C. abortus (log IFU/mL) of each group was
compared using ANOVA in SAS.
In the pregnant mice trial, the percentage of reproductive
disorders caused by C. abortus and the percentage of liver and
uterus samples with C. abortus per group were compared using
the chi-squared test within PROC FREQ in SAS. The number of
pups per litter of each group was compared using ANOVA in
SAS. The amount of C. abortus isolated in the liver and uterus
samples was compared using the Kruskal-Wallis test within
PROC NPAR1WAY of SAS; therefore, data were not parametric.
Dunn’s test was used to compare the pairs.
In the ovine experiment, the number of reproductive incidents
(abortions in late pregnancy, premature lambing or the birth of
weak lambs with early mortality) caused by the experimental
infection of C. abortus (confirmed by PCR) per day, from
challenge to the end of the study, was analyzed using the Fisher’s
exact (2-sided) test within PROC FREQ in SAS.
Vaginal swab samples collected from abortion or parturition
to 21 days after were used to determine the degree and duration
of C. abortus shedding. Shedding of C. abortus detected on the
day of abortion/parturition per group were used to compare
groups. After parturition or abortion, at least 9 further samples
were collected per animal, on Monday, Wednesday and Friday.
Thus, depending on the day of parturition or abortion, samples
were collected on different days. To summarize these data,
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an average per animal was calculated at these different time
intervals: D0–D3, D4–D6, D7–D9, D10–D12, D13–D15, D16–
D18, and D19–D21 post-partum/abortion. The area under the
curve (AUC) of shedding of C. abortus from abortion or
parturition to 21 days after was calculated for each ewe using
the data gathered from this period. One value per ewe was
obtained, estimating the total amount of shedding (expressed
in number of genome copies of C. abortus per sample) from
abortion or parturition to 21 days after. The shedding of
C. abortus detected on the day of abortion/parturition per
group were also used to compare groups. The amount of
C. abortus isolated in the vaginal swab samples on the day
of abortion/parturition, at different intervals detailed above
and during the 21 days after abortion/parturition (AUC),
were compared using the Kruskal-Wallis test within PROC
NPAR1WAY of SAS; therefore, data were not parametric
Dunn’s test was used to compare the pairs. The percentage
of samples positive by PCR against C. abortus on the day of
abortion/parturition and from abortion or parturition to 21 days
after per group was compared using the Fisher’s exact (2-sided)
test within PROC FREQ in SAS.
Rectal temperature data around the day of challenge per group
were compared using PROC MIXED in SAS (SAS Institute Inc.,
Cary, NC), treating a day as a repeated measure. The model
included the fixed effects of day, treatment, day-by-treatment
interaction, and the random effect of animal within treatment.
Compound symmetry was selected as the variance-covariance
matrix structure on the basis of best fit according to Schwarz’s
Bayesian information criterion. A rectal temperature in ewes
between 39.0 and 40.0◦C (35) was considered normal. The
temperature data were converted into binomial, normal values
(<40.0◦C) or abnormal values (>40.0◦C). These data per day
were analyzed using the chi-squared test within PROC FREQ
in SAS.
The body weight of lambs per group was compared using
the Student’s t-test in SAS per day. All values reported are least
squares means. Significance was declared at P < 0.05.
RESULTS
Results of Experiment 1 (Mice)
Adverse Reactions to Vaccines
No clinical signs or macroscopic lesions were observed in mice
vaccinated with the experimental UMU vaccine or PBS control
groups. In contrast, the INMEVA vaccinated mice showed
swelling measuring 0.4–0.9 cm at 1–2 weeks after the primary
and secondary administration. These local reactions disappeared
without treatment 3 weeks after vaccination. However, no animal
showed signs of pain, like squeaking, vocalizing or struggling,
on palpation.
Effect of Vaccines on Protection in a Non-pregnant
Mouse Model
Immunized non-pregnant mice were challenged on day 33 post-
boost administration (day 47 of study) with the AB7 strain of
C. abortus. The infected control group showed high morbidity,
with acute signs of disease such as weakness, ruffled fur, lethargy
and a substantial reduction in body weight, while none of the
vaccinated animals showed clinical signs. However, the UMU
immunized mice had significantly (P < 0.05) higher body weight
and body weight gain compared to immunized with the INMEVA
vaccine and compared to the control group at day 4 post-
infection (Table 1). A lower number of bacteria in the liver was
isolated in the mice vaccinated with UMU, showing significant
differences (P < 0.05) compared to INMEVA and control groups.
Furthermore, animals vaccinated with INMEVA had significantly
(P < 0.05) lower C. abortus isolation from liver than those of the
control group (Table 1).
Effect of Vaccines on Protection in a Pregnant Mouse
Model
Immunized pregnant mice were challenged on day 33 post-
boost administration (day 12 of gestation, day 47 of study)
under the same conditions as non-pregnant mice, and animals
were monitored to evaluate the reproductive disorders caused
by C. abortus as well as the presence of the microorganism
in the liver and uterus on day 11 post-challenge. None of the
UMU immunized mice showed abortions unlike the 25% of
the INMEVA immunized mice, but no significant differences
were noticed between these two vaccinated groups. On the
other hand, 89% of the control mice had abortions, which
was significantly (P < 0.05) higher compared to vaccinated
or sentinel groups (Table 2), showing significant differences
between vaccinated and non-vaccinated groups. Similarly, the
number of pups per mouse was significantly (P < 0.05) higher
in the vaccinated than in the control group. In addition, the
percentage of presence of C. abortus as well as the load of
microorganisms from liver and uterus collected was significantly
lower in vaccinated animals than in the control group. No
significant differences were observed between the two vaccinated
groups (Table 2).
Results of Experiment 2 (Ewes)
Safety After Vaccination
After vaccination, clinical signs were evaluated and animal
behavior was considered normal during the monitoring period.
The daily rectal temperatures of vaccinated and control sheep
were similar after vaccination and no increase was detected in
any group (data not shown). No alterations were observed in
vaccinated or control animals during the gestation period from
time of vaccination to the ultrasound detection of gestation and
fetal viability on day 45 post-mating. No significant differences in
terms of percentage of gestation were observed among groups,
where 19 out of the 30 vaccinated ewes, 21 out of the 30
control ewes and 10 out of the 20 sentinel ewes became pregnant
after mating.
Reproductive Incidences Related to C. abortus and
Shedding After Challenge
Thirteen days after challenge, a vaccinated animal suffered
a traumatic abortion, as this animal was accidentally caught
at the trough for several hours. Samples from the fetus and
placenta were collected and no lesions suggesting infectious
abortion were found. Moreover, the samples tested negative to
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TABLE 1 | Average body weight on day 47 (challenge day) and 51 of study, percentage of difference in bodyweight from day 47 to 51 and C. abortus isolation from liver
samples (log IFU/g of tissue) of non-pregnant challenged mice of each group.
INMEVA UMU Control group
Body weight D47 (Challenge day) 29.8 ± 0.73b 29.6 ± 0.68b 32.1 ± 0.82a
D51 27.7 ± 0.81b 30.2 ± 0.67a 28.3 ± 0.53b
Body weight gain (%) −7.21 ± 1.42b 1.97 ± 0.57a −11.8 ± 1.71b
C. abortus isolation
Percentage of animals with C. abortus 6/6 (100%) 5/5 (100%) 5/5 (100%)
Log10 IFUs/g (Mean ± SEM) 5.78 ± 0.29
b 4.26 ± 0.26c 6.83 ± 0.07a
Different superscript letters per row (a,b, c) indicate significant differences (P < 0.05) between groups.
TABLE 2 | Presence of reproductive disorders caused by C. abortus, average number of pups per mice, the percentage of liver and uterus samples with presence of C.
abortus and the average titration of C. abortus from liver and uterus samples (log IFU/g of tissue) of pregnant mice per group.
INMEVA UMU Control Sentinel
Reproductive disorders caused by C. abortus 2/8 (25%)b 0/11 (0%)b 8/9 (89%)a 0/9 (0%)b
Number of pups per mice (Mean ± SEM) 8.63 ± 1.78a 12.91 ± 1.11a 1.89 ± 1.11b 12.11 ± 1.07a
C. abortus isolation (liver)
Percentage of animals with C. abortus 2/8 (25%)a 2/11 (18%)a 8/9 (89%)b 0/9 (0%)a
Log10 IFUs/g (Mean ± SEM) 0.79 ± 0.52
b 0.47 ± 0.32b 3.17 ± 0.44a 0.00b
C. abortus isolation (uterus)
Percentage of animals with C. abortus 2/8 (25%)a 0/11 (0%)a 8/9 (89%)b 0/9 (0%)a
Log10 IFUs/g (Mean ± SEM) 0.94 ± 0.62
b 0.00b 3.90 ± 0.27a 0.00b
Different superscript letters per row (a,b) indicate significant differences (P < 0.05) between groups.
C. abortus by PCR, confirming that this abortion was unrelated
to the infection. Consequently, this animal was eliminated from
the study. Therefore, the vaccine efficacy was tested using 18
vaccinated animals.
Two control group abortions were reported during the
gestation period. Both ewes aborted two fetuses and all samples
collected from these abortions (vaginal swabs, placenta and fetus
samples) were positive to C. abortus by PCR. A severe subacute
and multifocal to coalescent suppurative and necrotic placentitis
was observed involving both cotyledons and intercotyledonary
membranes (Figure 2A). Immunohistochemical labeling showed
abundant chlamydial antigen within the fetal necrotic villi in
these samples (Figure 2B). Afterward, three ewes from the
control group had stillbirths in a premature parturition, where
all samples collected were also positive to C. abortus by PCR.
Histological lesions in these cases were milder than those found
in the samples from abortions and characterized by a moderate
multifocal suppurative placentitis, mainly affecting the base of
the placentomes. These lesions appeared as discrete foci of
inflammatory cells, mainly neutrophils, within the caruncular
villi (Figure 2C). Immunohistochemical labeling showed focal
accumulation of chlamydial antigen in cotyledonary villi
adjacent to the foci of inflammatory cells at the caruncular
villi (Figure 2D)
After that, four control and two vaccinated ewes gave birth to
weak lambs, which died between 1 and 8 days after parturition
and all samples collected were also positive to C. abortus by PCR,
confirming the involvement ofC. abortus in the perinatal death of
the lambs. No other reproductive incidences related to C. abortus
were noticed during the study. Consequently, the percentage
of reproductive incidences was significantly (P < 0.05) greater
in the control group compared to vaccinated and sentinel
ewes (Table 3).
Regarding shedding, the percentage of samples positive to C.
abortus by PCR in vaginal swabs after abortion or parturition
was significantly (P < 0.05) high in control ewes compared to
vaccinated and sentinel groups (Table 3). As a result, the amount
of shedding of C. abortus the day of abortion or parturition was
also significantly higher (P < 0.05) in control animals than in
vaccinated and sentinel groups (Table 3).
After abortion or parturition, as shown in Figure 3,
control ewes had significantly (P < 0.05) higher shedding
of C. abortus than vaccinated and sentinel ewes from
abortion/parturition to 15 days after and between 19 and
21 days after abortion/parturition. Overall, the AUC of total
shedding from abortion or parturition to 21 days after was
significantly (P < 0.05) greater in the control group than those
of the vaccinated and sentinel groups (Table 3). Furthermore,
the percentage of samples positive to C. abortus in vaginal swabs
from abortion or parturition to 21 days after was significantly (P
< 0.05) higher in control animals compared to vaccinated and
sentinel ewes (Table 3).
Post-challenge Rectal Temperatures
Rectal temperature values before challenge were similar in all
groups. One day after challenge, the infected groups (vaccinated
and control) presented an increase in average temperature, as
shown in Figure 4. The control group had significantly (P <
0.05) higher rectal temperatures compared to the vaccinated
and sentinel group. The vaccinated group had significantly
higher rectal temperatures compared to the sentinel group
(P < 0.05) 1 day after challenge. Afterwards, rectal temperatures
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FIGURE 2 | (a) Ovine placenta, midgestation, from an unvaccinated aborted fetus (positive control). Severe multifocal necro-suppurative placentitis. The inflammatory
cell infiltrate, primarily neutrophils and cellular debris, was in the villous projections of the maternal caruncle (arrows). HE. 10x. (b) The Chlamydial antigen (brown
pigment) was present within necrotic villous projections of the fetal cotyledons (arrowhead). There was little to no labeling within the inflammatory cell infiltrate present
within the maternal caruncles (arrow). Semi-serial section of (a). Chlamydial antigen IHC. 10x. (c) Placental sample from a stillborn unvaccinated animal (positive
control). Mild suppurative placentitis as denoted by a single focus of inflammatory cells, primarily neutrophils, within a villous projection of the maternal caruncle (arrow).
HE. 10x. (d) Semi-serial section of (c). Similar to figure (b), the chlamydial antigen (brown pigment) was present mostly in the cellular debris within the fetal cotyledon
(arrowhead). There was little to no labeling within the inflammatory cell infiltrate within the tissue of the maternal caruncles (arrow). Chlamydial antigen IHC. 10x.
TABLE 3 | Presence of reproductive disorders caused by C. abortus, the percentage of vaginal swab samples with presence of C. abortus and the average titration of C.
abortus from vaginal swab samples (numbers of genome copies of C. abortus per sample) of pregnant ewes per group.
Vaccinated Control
Reproductive disorders caused C. abortus 2/18 (11%)b 9/21 (43%)a
C. abortus at parturition/abortion
Percentage of animals with C. abortus 7/18 (39%)b 18/21 (86%)a
Log10 genome copies 2.03 ± 0.62
b 5.11 ± 0.51a
C. abortus from parturition/abortion to 21 days after
Percentage of samples with C. abortus 35/179 (20%)b 131/210 (62%)a
Log10 genome copies (AUC) 2.46 ± 0.54
b 5.11 ± 0.31a
Different superscript letters per row (a,b) indicate significant differences (P < 0.05) between groups.
decreased in these groups. Infected groups had significantly (P
< 0.05) higher rectal temperatures than sentinel group 2 days
after challenge. The percentage of animals with temperatures
over 40◦C in the infected groups was also significantly (P <
0.05) greater than the sentinel group (Figure 4). Three days
after challenge, no significant differences were observed among
vaccinated and sentinel groups in terms of average rectal
temperature and percentage of animals over 40◦C. However,
the control group had a significantly (P < 0.05) higher
average for rectal temperatures compared to the sentinel group
(Figure 4). No significant differences were observed among
all groups 4 days after challenge, but 5 days after challenge
the average of rectal temperature of the control group was
significantly (P < 0.05) higher than those of the vaccinated and
sentinel groups.
Body Weight of Lambs
The body weight of lambs from the control group was
significantly (P < 0.05) lower than that of lambs from the
vaccinated and sentinel groups at birth and 4 days after
parturition (Figure 5). From 7 to 28 days after parturition, lambs
from control ewes had significantly (P < 0.05) lower body
weight than lambs from the sentinel group, but no differences
were observed between the vaccinated and control groups. No
significant differences were observed between lambs from the
vaccinated group and sentinel group during the whole study.
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FIGURE 3 | Geometric means of daily shedding (Log10 of number of genome copies of C. abortus per vaginal swab ± SEM) of control, vaccinated and sentinel group
from abortion/parturition to 21 days after experimental infection. *Indicates significant differences (P < 0.05) between the control and other groups (vaccinated and
sentinel).
FIGURE 4 | Average of rectal temperatures and percentage of animals with temperatures over 40◦C from vaccinated and control groups from challenge to day 5 after
experimental infection. Different superscript letters (a,b, c) indicate significant differences (P < 0.05) between groups in terms of rectal temperatures (◦C) per day.
*Indicates significant differences (P < 0.05) between infected groups (vaccinated and control) compared to the sentinel group in terms of percentage of animals over
40◦C.
DISCUSSION
OEA is one of the abortion diseases with the greatest economic
impact worldwide, in terms of small ruminant production. One
of the measures for chlamydial disease control is vaccination
using commercial attenuated or inactivated vaccines. However,
several authors (27, 36, 37) have questioned the efficacy of
most of the current inactivated commercial vaccines. Regarding
live vaccines, recently some researchers have warned about
attenuated strain 1B, associating it with increase of OEA
outbreaks in flocks vaccinated with this live vaccine (18, 19).
For this reason, research continues to focus on a commercial
product that must be effective, safe, and economically viable.
The present study has shown that INMEVA, a recently
commercialized inactivated vaccine developed against OEA, is
effective in promoting a significant decrease in the number
of reproductive failures and minimizing chlamydial shedding
at delivery.
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FIGURE 5 | Average of lamb body weights per group from birth to 28 days after birth per day. a Indicates significant differences (P < 0.05) between the control and
other groups (vaccinated and sentinel). b Indicates significant differences (P < 0.05) between the control and sentinel group.
The effectiveness of a vaccine candidate may be linked to
several factors such as the amount of antigen present, the
inactivation method used, the choice of adjuvant(s), or the
frequency of administration [reviewed in (38)]. Nevertheless,
validating all these aspects in the relevant host using a
pregnant sheep model would be excessively expensive and time-
consuming. Due to this fact, mouse models have been considered
as a useful economic tool to evaluate new vaccine candidates
that prevent abortion and decrease chlamydial shedding sharply
[reviewed in (29)]. Therefore, when developing the INMEVA
vaccine, the choice of the inactivation method, the amount of
antigen included in the formulation, as well as the adjuvant
selected, were based on experimental mouse models (data
not shown). Thus, experiment 1 shows the results of the
INMEVA vaccine comparing them with the efficacy results
obtained with an experimental inactivated vaccine widely used
in different studies (i.e., the UMU vaccine). This UMU vaccine
was previously tested on murine and ovine models, both
with systemic (28, 36) and local (39–41) challenge, showing
exceptionally good protective results in all cases. In these studies,
the strain used to conduct these challenges was the same strain
used to develop the UMU vaccine.
In the non- pregnant model, the UMU vaccine was more
effective than the INMEVA vaccine, with respect to body weight
or the presence of C. abortus in the liver. However, no significant
differences were found between both vaccines in the pregnant
model in terms of reproductive failure, pup number per mouse
or the presence of C. abortus in the liver or uterus. The proven
efficacy of both vaccines in the mice-pregnant model indicates
that the antigen they contain confers the desired immunity
response. The antigen of both vaccines tested were inactivated
by an inactivating agent that acts on nucleic acids, but it
preserved the integrity of the protein antigens. It has been
reported that other chemicals, such as formaldehyde (27, 28, 42)
and glutaraldehyde (10, 43) have been incorporated into the
formulation of vaccines, both experimental and commercial,
against OEA. But chemicals like these can destroy proteins, such
as the polymorphic outer membrane proteins -POMPs- (44) and
the oligomeric form of the MOMP (20) that may be essential
to induce an adequate protective immune response; hence, the
alteration of these proteins would decrease the effectiveness of
this inactivated vaccine. In addition, a suitable inactivated vaccine
must include an appropriate adjuvant that enhances an effective
immune response. It has been shown that the adjuvant used in
the formulation plays an important role in defining the immune
response induced (cellular and/or humoral). Furthermore, it is
known that a cellular immune response with relevant IFN-γ
production is important in solving infection fromC. abortus both
in mice (45) and ovine (38). The adjuvant of INMEVA vaccine
combines aluminum hydroxide and DEAE-dextran. Aluminum
salts promotes formation of multimolecular aggregates, when it
interacts with the antigen and these aggregates or multimolecular
structure are more easily phagocytized (46). Moreover, DEAE-
Dextran is commonly used to facilitate the infection of cell
cultures in vitro (33) as it is amolecule that enhances the adhesion
of Chlamydiae to target cells, which may increase the amount
of antigen reaching the antigen presenting cells located in the
immunization zone (46).
Once development in murine model was completed, the
definitive validation of the efficacy of the vaccine must be
performed in pregnant sheep models, since this ruminant species
is the natural host ofC. abortus. Thus, in experiment 2 the efficacy
of the INMEVA vaccine was assessed comparing the reproductive
failures and the bacterial shedding as well as the evaluation of
the weight gain by the offspring, in relation to an unvaccinated
infected control group. The experimental challenge caused a
slight but significant increase in rectal temperature: 1◦C for 2
consecutive days in both infected groups, as previously described
(36, 37, 42, 47), showing that both groups were effectively
challenged. Furthermore, the abortions and stillbirths suffered
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by the control non-vaccinated animals showed similar lesions,
i.e., multifocal to coalescent suppurative placentitis with variable
degree of severity, to those described in previous experimental
studies on OEA (32). The results on reproductive performance
and bacterial shedding showed that this new commercial vaccine,
in addition to being safe, also provides a remarkable level of
protection against an experimental challenge of C. abortus in
pregnant sheep. These data are based on a 75% reduction in
reproductive disorders and a 55% reduction in animals shedding
C. abortus on the day of parturition/abortion when compared to
the infected control group. In addition, the average amount of
chlamydial shedding, measured in number of C. abortus genome
copies, is about 1,000 times lower in vaccinated animals, not
only on the day of parturition/abortion, but over the next 21
days when vaginal swabs are collected. This fact is essential
because it could contribute to lessening the risk of transmission,
as ewes and lambs become infected around parturition when
large amounts of Chlamydiae are released, thereby favoring the
infection of naïve animals, via ingestion or inhalation (2, 4). The
protection results shown by the INMEVA vaccine are notably
better than those reported by other commercial inactivated
vaccines previously tested in similar pregnant ovine models,
where the decrease in reproduction failures did not reach 10%
in relation to infection control (11, 36, 37). Likewise, these
commercial vaccines did not show a significant decrease in
the bacterial shedding after parturition/abortion, and a positive
effect from vaccination was observed on offspring growth in
the vaccinated group compared with the control group (37).
Although to a lesser extent, this effect on the bodyweight of lambs
has also been observed in animals vaccinated with INMEVA,
since lambs from the control group had significantly lower body
weights than lambs from the vaccinated and sentinel groups in
the first 4 days after birth.
In relation to the inactivated experimental vaccines against
OEA, the UMU vaccine was used in this paper as a positive
protection control in the murine model. The UMU vaccine
was also tested in a previous study in the pregnant ovine
model obtaining similar efficacy (72%) compared to INMEVA
(75%), considering the reduction of reproductive failures in
the vaccinated animals in relation to the infection controls
(36). However, the antigen production method used in the
UMU vaccine, with a partial purification of chlamydia (28),
is difficult to apply at the industrial stage, and would
considerably increase production costs. On the other hand,
considering the efficacy of recombinant vaccines, in a very recent
study carried out with an experimental vaccine that used a
combination of recombinant MIP and CPAF from C. abortus
(24), the experimental vaccine reached 50% efficacy, with a
decrease in abortions in the vaccinated group in comparison
to the infection control group. However, although vaccinated
animals showed less shedding of C. abortus on the vaginal
swab compared to the infected control group, this difference
was not statistically significant. The current investigation is
focused toward this type of subcellular vaccines by targeting
proteins (48), but researchers indicate that further studies are
needed to improve protection outcomes and achieve viable
economic industrial production for marketing on the part of
pharmaceutical companies.
CONCLUSION
The results obtained in this study have shown that the INMEVA
commercial inactivated vaccine is safe, showing a suitable level
of protection against OEA related to a significant decrease
in reproductive failures and in chlamydial shedding, thereby
limiting spread of infection in the flock. In addition, this
vaccine has minimized the weight loss of the lambs at birth
and during the first week of life. In summary, this vaccine
confers protection to animals challenged with Chlamydia abortus
in the pregnant sheep model and mice models; thus, the
results shown indicate that this commercial vaccine is adequate
for controlling and preventing OEA. However, future studies
are necessary to elucidate the type of protective immune
response that INMEVA induces and how it is associated with
its effectiveness.
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